241 related articles for article (PubMed ID: 11691805)
21. The effect of modulation of glutathione cellular content on busulphan-induced cytotoxicity on hematopoietic cells in vitro and in vivo.
Hassan Z; Hellström-Lindberg E; Alsadi S; Edgren M; Hägglund H; Hassan M
Bone Marrow Transplant; 2002 Aug; 30(3):141-7. PubMed ID: 12189531
[TBL] [Abstract][Full Text] [Related]
22. Potentiation of the cytostatic effect of melphalan on colorectal cancer hepatic metastases by infusion of buthionine sulfoximine (BSO) in the rat: enhanced tumor glutathione depletion by infusion of BSO in the hepatic artery.
Vahrmeijer AL; van Dierendonck JH; Schutrups J; van de Velde CJ; Mulder GJ
Cancer Chemother Pharmacol; 1999; 44(2):111-6. PubMed ID: 10412944
[TBL] [Abstract][Full Text] [Related]
23. Growth of human lung tumor in the brain of the nude rat as a model to evaluate antitumor agent delivery across the blood-brain barrier.
Neuwelt EA; Frenkel EP; D'Agostino AN; Carney DN; Minna JD; Barnett PA; McCormick CI
Cancer Res; 1985 Jun; 45(6):2827-33. PubMed ID: 2985254
[TBL] [Abstract][Full Text] [Related]
24. Buthionine sulfoximine causes endothelium dependent hyper-relaxation and hypoadiponectinemia.
Iwata C; Wang X; Uchida K; Nakanishi N; Hattori Y
Life Sci; 2007 Feb; 80(9):873-8. PubMed ID: 17137603
[TBL] [Abstract][Full Text] [Related]
25. Phase I study of continuous-infusion L-S,R-buthionine sulfoximine with intravenous melphalan.
Bailey HH; Ripple G; Tutsch KD; Arzoomanian RZ; Alberti D; Feierabend C; Mahvi D; Schink J; Pomplun M; Mulcahy RT; Wilding G
J Natl Cancer Inst; 1997 Dec; 89(23):1789-96. PubMed ID: 9392620
[TBL] [Abstract][Full Text] [Related]
26. Effect of N-acetyl-cysteine, D-penicillamine and buthionine sulfoximine on glutathione levels and CNS oxygen toxicity in rats.
Lalitha T; Kerem D; Yannai S
Pharmacol Toxicol; 1990 Jan; 66(1):56-61. PubMed ID: 2308909
[TBL] [Abstract][Full Text] [Related]
27. Enhanced melphalan cytotoxicity following buthionine sulfoximine-mediated glutathione depletion in a human medulloblastoma xenograft in athymic mice.
Skapek SX; Colvin OM; Griffith OW; Elion GB; Bigner DD; Friedman HS
Cancer Res; 1988 May; 48(10):2764-7. PubMed ID: 3359437
[TBL] [Abstract][Full Text] [Related]
28. Protection against cisplatin-induced ototoxicity by N-acetylcysteine in a rat model.
Thomas Dickey D; Muldoon LL; Kraemer DF; Neuwelt EA
Hear Res; 2004 Jul; 193(1-2):25-30. PubMed ID: 15219317
[TBL] [Abstract][Full Text] [Related]
29. Glutathione depletion by buthionine sulfoximine induces oxidative damage to DNA in organs of rabbits in vivo.
Gokce G; Ozsarlak-Sozer G; Oktay G; Kirkali G; Jaruga P; Dizdaroglu M; Kerry Z
Biochemistry; 2009 Jun; 48(22):4980-7. PubMed ID: 19374446
[TBL] [Abstract][Full Text] [Related]
30. Increased delivery of erucylphosphocholine to C6 gliomas by chemical opening of the blood-brain barrier using intracarotid pentylglycerol in rats.
Erdlenbruch B; Jendrossek V; Kugler W; Eibl H; Lakomek M
Cancer Chemother Pharmacol; 2002 Oct; 50(4):299-304. PubMed ID: 12357304
[TBL] [Abstract][Full Text] [Related]
31. Glutathione depletion in vivo enhances contraction and attenuates endothelium-dependent relaxation of isolated rat aorta.
Ford RJ; Graham DA; Denniss SG; Quadrilatero J; Rush JW
Free Radic Biol Med; 2006 Feb; 40(4):670-8. PubMed ID: 16458198
[TBL] [Abstract][Full Text] [Related]
32. Fluoride-induced genotoxicity in mouse bone marrow cells: effect of buthionine sulfoximine and N-acetyl-L-cysteine.
Podder S; Chattopadhyay A; Bhattacharya S; Ray MR; Chakraborty A
J Appl Toxicol; 2011 Oct; 31(7):618-25. PubMed ID: 21154881
[TBL] [Abstract][Full Text] [Related]
33. In vivo therapeutic potential of combination thiol depletion and alkylating chemotherapy.
Siemann DW; Beyers KL
Br J Cancer; 1993 Dec; 68(6):1071-9. PubMed ID: 8260357
[TBL] [Abstract][Full Text] [Related]
34. The chemoprotective agent N-acetylcysteine blocks cisplatin-induced apoptosis through caspase signaling pathway.
Wu YJ; Muldoon LL; Neuwelt EA
J Pharmacol Exp Ther; 2005 Feb; 312(2):424-31. PubMed ID: 15496615
[TBL] [Abstract][Full Text] [Related]
35. Effect of antigenic heterogeneity on the efficacy of enhanced delivery of antibody-targeted chemotherapy in a human lung cancer intracerebral xenograft model in rats.
Muldoon LL
Neurosurgery; 2003 Dec; 53(6):1406-12; discussion 1412-3. PubMed ID: 14633307
[TBL] [Abstract][Full Text] [Related]
36. Pharmacologic modulation of reduced glutathione circadian rhythms with buthionine sulfoximine: relationship with cisplatin toxicity in mice.
Li XM; Metzger G; Filipski E; Boughattas N; Lemaigre G; Hecquet B; Filipski J; Levi F
Toxicol Appl Pharmacol; 1997 Apr; 143(2):281-90. PubMed ID: 9144445
[TBL] [Abstract][Full Text] [Related]
37. Enhancement of arsenic trioxide-induced apoptosis in renal cell carcinoma cells by L-buthionine sulfoximine.
Wu XX; Ogawa O; Kakehi Y
Int J Oncol; 2004 Jun; 24(6):1489-97. PubMed ID: 15138592
[TBL] [Abstract][Full Text] [Related]
38. Antagonism of buthionine sulfoximine cytotoxicity for human neuroblastoma cell lines by hypoxia is reversed by the bioreductive agent tirapazamine.
Yang B; Keshelava N; Anderson CP; Reynolds CP
Cancer Res; 2003 Apr; 63(7):1520-6. PubMed ID: 12670899
[TBL] [Abstract][Full Text] [Related]
39. Use of N-acetyl cysteine to increase intracellular glutathione during the induction of antitumor responses by IL-2.
Yim CY; Hibbs JB; McGregor JR; Galinsky RE; Samlowski WE
J Immunol; 1994 Jun; 152(12):5796-805. PubMed ID: 8207209
[TBL] [Abstract][Full Text] [Related]
40. Impact of 30-day oral dosing with N-acetyl-L-cysteine on Sprague-Dawley rat physiology.
Arfsten D; Johnson E; Thitoff A; Jung A; Wilfong E; Lohrke S; Bausman T; Eggers J; Bobb A
Int J Toxicol; 2004; 23(4):239-47. PubMed ID: 15371168
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
